Market capitalization | $20.48b |
Enterprise Value | $37.35b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 18.01 |
EV/Sales (TTM) EV/Sales | 2.29 |
P/S ratio (TTM) P/S ratio | 1.26 |
P/B ratio (TTM) P/B ratio | 3.22 |
Revenue growth (TTM) Revenue growth | 8.38% |
Revenue (TTM) Revenue | $16.30b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:
11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 16,301 16,301 |
8%
8%
|
|
Gross Profit | 8,073 8,073 |
18%
18%
|
|
EBITDA | 4,592 4,592 |
21%
21%
|
EBIT (Operating Income) EBIT | 3,512 3,512 |
37%
37%
|
Net Profit | -443 -443 |
80%
80%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Head office | Israel |
CEO | Richard Francis |
Employees | 37,226 |
Founded | 1901 |
Website | www.tevapharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.